Where the Street stands
These are third-party analyst opinions from named firms, not advice, and not a prediction. How we score this
23 firms currently rating it, weighted by track record.
The 21 firms with a track record here beat the S&P 40% of the time over 12 months.
Pro: see the crowd-vs-sharp split for ABBVAnalysts rate AbbVie as a consensus Buy, with 25 of 29 ratings at Buy or better and a $277.31 average price target implying 7.9% upside from current levels. Wolfe Research upgraded the stock to Outperform on August 13, citing a move from Peer Perform. The pharmaceutical giant is growing revenues 10.2% year-over-year with earnings up 290.4%, though it trades at a trailing P/E of 72.43 against a forward multiple of 15.79, reflecting elevated near-term valuations relative to projected normalized earnings. With a low beta of 0.28 and 72.79% gross margins, the stock reflects a defensive healthcare positioning within a $454.4 billion market cap.
Generated from the data on this page; may contain errors. Analyst opinions belong to the named firms. Informational only, not investment advice.
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 10, 2026 | HSBC | ○ Maintained | |
| Aug 20, 2026 | Piper Sandler | ○ Maintained |
Create a free account to unlock all analyst ratings, key stats, and news. No credit card, takes 30 seconds.
Sign up free